Zanzalintinib and pembrolizumab before kidney cancer surgery
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of two drugs, zanzalintinib and pembrolizumab, given before surgery for clear cell kidney cancer that has not spread too far. The goal is to see if the drugs help shrink the tumor and make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of kidney cancer called clear cell renal cell carcinoma that can be removed with surgery.
- You must be 19 years or older.
- You must be in good enough health to be up and about (ECOG score 0 or 1).
- You cannot have had prior treatment with drugs like anti-PD-1 or VEGFR inhibitors.
- You must have at least one tumor that can be measured on scans.
- Your major organs (blood, liver, kidneys) must be working well enough based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs—zanzalintinib and nivolumab—given before surgery to shrink advanced or hard-to-remove kidney tumors. The goal is to make the tumor easier to remove and improve outcomes.
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
This trial is testing if adding the targeted therapy tivozanib to the immunotherapy drug pembrolizumab (Keytruda) can help prevent kidney cancer from coming back after all known tumors have been removed by surgery.
This trial tests a new drug called zanzalintinib for people with advanced clear cell kidney cancer that has spread to the bones (at least 3 spots). The study wants to see if this drug can help slow down or shrink the cancer. It's for patients who have already had some prior treatments.
This trial tests two new drugs, belzutifan and zanzalintinib, for people with advanced kidney cancer that returned after or within 2 years of finishing an immunotherapy treatment after surgery. You cannot have received any other cancer treatments besides that immunotherapy.
Hear when a new Patients With Locally Advanced or Metastatic But Resectable Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.